Irish Biotech Startup Aerska Secures $21M to Push Boundaries of Brain RNAi Therapies
Aerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read moreAerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read moreA recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read moreRetinal degeneration represents a primary cause of irreversible blindness, with both its onset and severity differing significantly among various conditions.
Read moreSanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read moreA groundbreaking study by Groh et al., recently featured in Nature Communications, delves into the interplay between adaptive immunity and
Read moreSangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read moreVentus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more3DProSeed Hydrogel Plate – Application Data – Cancer Research and CNS A Ectica Technologies Case Study The 3DProSeed Hydrogel Plate developed
Read more